Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more than 35% rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss drug market. Once … Read more
The kids are alright — on GLP-1s, that is. A new study found that blockbuster treatments like Mounjaro and Zepbound can dramatically lower blood sugar and body weight in children as young as 10 with Type 2 diabetes. The data could help pave the way for younger patients to access the shots, as drugmaker Eli … Read more
It’s easy to make a medical case for blockbuster weight loss drugs like Wegovy and Zepbound, which have been shown to prevent heart attacks and strokes and save lives. But for the employers and government programs being asked to pay for the medications, the financial case for them is less clear. Are the drugs’ benefits … Read more
Eli Lilly on Thursday launched a website to enable people to directly order from the drugmaker including its weight-loss medicine Zepbound as well as connect people with obesity and other conditions with telehealth companies. The service, called LillyDirect, comes on the back of extraordinary demand seen over the last year for powerful weight-loss drugs such as Novo Nordisk’s Wegovy. … Read more
Move over, Ozempic — there’s a new drug in town. Eli Lilly’s Zepbound, with the active ingredient tirzepatide, has been approved by the Food and Drug Administration for use by obese or overweight adults who have at least one weight-related health complication, like Type 2 diabetes, high blood pressure or high cholesterol. Tirzepatide, sold as Mounjaro, … Read more